Cellular Goods PLC Director's Dealings (1385Z)
January 10 2024 - 1:00AM
UK Regulatory
TIDMCBX
RNS Number : 1385Z
Cellular Goods PLC
10 January 2024
The information contained within this announcement is deemed by
the Company to constitute inside information stipulated under the
Market Abuse Regulation (EU) No. 596/2014, as retained as part of
the law of England and Wales. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
10 January 2024
Cellular Goods PLC
("Cellular Goods" or "The Company")
Director's Dealings
Cellular Goods (LSE: CBX), a UK-based company pioneering the use
of lab-based and biosynthetic production methods for wellness and
sustainability solutions, announces that Michael Edwards (Executive
Director of Cellular Goods) has purchased a total of 2,500,000
ordinary shares in the Company ("Ordinary Shares"), the details of
which are set out in the notification below. F ollowing this
purchase, Michael Edwards holds a total of 8,000,000 Ordinary
Shares, representing 1.33 per cent of the Company's issued share
capital.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
1. / person closely associated
a) Name Michael Edwards
------------------------------ -------------------------------------
Reason for the Notification
2.
---------------------------------------------------------------------
a) Position/status Executive Director
------------------------------ -------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------ -------------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Cellular Goods PLC
------------------------------ -------------------------------------
b) LEI 213800IXPX4Z2MKX2U28
------------------------------ -------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary shares
Financial instrument,
type of instrument
Identification Code GB00BK964W87
------------------------------ -------------------------------------
b) Nature of the transaction Purchase of shares
------------------------------ -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.417 pence 2,500,000 Ordinary
per Ordinary Shares
Share
-------------------
------------------------------ -------------------------------------
d) Aggregated information:
* Aggregated volume 2,500,000 Ordinary Shares
0.417 pence per Ordinary Share
* Price
------------------------------ -------------------------------------
e) Date of the transaction 09 January 2024
------------------------------ -------------------------------------
f) Place of the Transaction London Stock Exchange
------------------------------ -------------------------------------
For further information please contact:
Cellular Goods
Michael Edwards via FSCF +44 7572 873 300
Director
--------------------------
First Sentinel Corporate Finance
(FSCF)
--------------------------
Investor Relations
Rebecca Noonan +44 7572 873 300
IR@cellular-goods.com
Media Relations
Rebecca Noonan +44 7572 873 300
Media@cellular-goods.com
Corporate Broker & Advisor
Brian Stockbridge +44 7858 888 007
--------------------------
Novum Securities
--------------------------
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
--------------------------
About Cellular Goods PLC:
Cellular Goods is pioneering the use of lab-based and
biosynthetic production methods for wellness and sustainability
solutions. The Company launched with a focus on efficacy led and
science-backed products utilising biosynthetics, and now employs
its expertise across two verticals: premium next-generation
cannabinoid skincare products, and carbon
sequestration-as-a-service through its wholly owned business
division, King Tide Carbon, which utilises biosynthetic algae and
seaweed to provide scalable carbon removal. The Company is
incorporated in the UK and listed on the Main Market of the London
Stock Exchange. For more information, visit www.cellular-goods.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDZGGMKLGGDZM
(END) Dow Jones Newswires
January 10, 2024 02:00 ET (07:00 GMT)
Cellular Goods (LSE:CBX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cellular Goods (LSE:CBX)
Historical Stock Chart
From Dec 2023 to Dec 2024
